## Receptor (biochemistry) +Search for Videos

Other uses|Receptor (disambiguation)

In biochemistry+ and pharmacology+, a '''receptor''' is a protein+ molecule+ that receives chemical signals from outside a cell. When such chemical signals bind to a receptor, they cause some form of cellular/tissue response, e.g. a change in the electrical activity of a cell. In this sense, a receptor is a protein-molecule that recognizes and responds to endogenous+ chemical signals, e.g. an acetylcholine receptor recognizes and responds to its endogenous ligand, acetylcholine+. However, sometimes in pharmacology, the term is also used to include other proteins that are drug targets, such as enzymes, transporters and ion channels.

Receptor protein+s are embedded in all cells' plasma membranes; facing extracellular (cell surface receptor+s), cytoplasmic (cytoplasmic receptors), or in the nucleus+, (nuclear receptor+s). A molecule that binds to a receptor is called a ligand+, and can be a protein+ or peptide+ (short protein), or another small molecule+ such as a neurotransmitter+, hormone+, pharmaceutical drug, toxin, or parts of the outside of a virus or microbe. The endogenously designated -molecule for a particular receptor is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine but the receptor can also be activated by nicotine+ and blocked by curare+.

Each receptor is linked to a specific cellular biochemical pathway. While numerous receptors are found in most cells, each receptor will only bind with ligands of a particular structure, much like how locks will only accept specifically shaped keys. When a ligand binds to its corresponding receptor, it activates or inhibits the receptor's associated biochemical pathway.

The structures of receptors are very diverse and can broadly be classified into the following categories:
* Type 1: L (ionotropic receptors)– These receptors are typically the targets of fast neurotransmitters such as acetylcholine (nicotinic) and GABA+; and, activation of these receptors results in changes in ion movement across a membrane. They have a heteromeric structure in that each subunit consists of the extracellular ligand-binding domain and a transmembrane domain where the transmembrane domain in turn includes four transmembrane alpha helices+. The ligand-binding cavities are located at the interface between the subunits.
* Type 2: G protein-coupled receptor+s (metabotropic) – This is the largest family of receptors and includes the receptors for several hormones and slow transmitters e.g. dopamine, metabotropic glutamate. They are composed of seven transmembrane alpha helices. The loops connecting the alpha helices form extracellular and intracellular domains. The binding-site for larger peptide ligands is usually located in the extracellular domain whereas the binding site for smaller non-peptide ligands is often located between the seven alpha helices and one extracellular loop. The aforementioned receptors are coupled to different intracellular effector systems via G proteins+.
* Type 3: Kinase-linked and related receptors (see "Receptor tyrosine kinase+", and "Enzyme-linked receptor+") - They are composed of an extracellular domain containing the ligand binding site and an intracellular domain, often with enzymatic-function, linked by a single transmembrane alpha helix. The insulin receptor+ is an example.
* Type 4: Nuclear receptor+s – While they are called nuclear receptors, they are actually located in the cytoplasm+ and migrate to the nucleus+ after binding with their ligands. They are composed of a C-terminal+ ligand-binding region, a core DNA-binding domain+ (DBD) and an N-terminal+ domain that contains the ''AF1''(activation function 1) region. The core region has two zinc fingers that are responsible for recognizing the DNA sequences specific to this receptor. The N terminus interacts with other cellular transcription factors in a ligand-independent manner; and, depending on these interactions, it can modify the binding/activity of the receptor. Steroid and thyroid-hormone receptors are examples of such receptors.

Membrane receptors may be isolated from cell membranes by complex extraction procedures using solvents+, detergents+, and/or affinity purification+.

The structures and actions of receptors may be studied by using biophysical methods such as X-ray crystallography+, NMR+, circular dichroism+, and dual polarisation interferometry+. Computer simulation+s of the dynamic behavior of receptors have been used to gain understanding of their mechanisms of action.

Ligand binding is an equilibrium+ process. Ligands bind to receptors and dissociate from them according to the law of mass action+.

:$\left\left[\mathrmLigand\right\right] \cdot \left\left[\mathrmReceptor\right\right]\;\;\oversetK_d\rightleftharpoons\;\;\left\left[\textLigand-receptor complex\right\right]$
: (the brackets stand for concentrations)

One measure of how well a molecule fits a receptor is its binding affinity, which is inversely related to the dissociation constant+ ''K''''d''. A good fit corresponds with high affinity and low ''K''''d''. The final biological response (e.g. second messenger cascade+, muscle-contraction), is only achieved after a significant number of receptors are activated.

Affinity is a measure of the tendency of a ligand to bind to its receptor. Efficacy is the measure of the bound ligand to activate its receptor.

Not every ligand that binds to a receptor also activates that receptor. The following classes of ligands exist:

* ''(Full) agonist+s'' are able to activate the receptor and result in a strong biological response. The natural endogenous+ ligand with the greatest efficacy+ for a given receptor is by definition a full agonist (100% efficacy).
* ''Partial agonist+s'' do not activate receptors with maximal efficacy, even with maximal binding, causing partial responses compared to those of full agonists (efficacy between 0 and 100%).
* ''Antagonists''+ bind to receptors but do not activate them. This results in a receptor blockade, inhibiting the binding of agonists and inverse agonists. Receptor antagonists can be competitive (or reversible), and compete with the agonist for the receptor, or they can be irreversible antagonists that form covalent bonds+ (or extremely high affinity non-covalent bonds) with the receptor and completely block it. The proton pump inhibitor omeprazole+ is an example of an irreversible antagonist. The effects of irreversible antagonism can only be reversed by synthesis of new receptors.
* ''Inverse agonist+s'' reduce the activity of receptors by inhibiting their constitutive activity (negative efficacy).
* ''Allosteric modulators+'': They do not bind to the agonist-binding site of the receptor but instead on specific allosteric binding sites, through which they modify the effect of the agonist. For example, benzodiazepines+ (BZDs) bind to the BZD site on the GABAA receptor+ and potentiate the effect of endogenous GABA.

Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects.

A receptor which is capable of producing a biological response in the absence of a bound ligand is said to display "constitutive activity". The constitutive activity of a receptor may be blocked by an inverse agonist+. The anti-obesity drugs rimonabant+ and taranabant+ are inverse agonists at the cannabinoid CB1 receptor+ and though they produced significant weight loss, both were withdrawn owing to a high incidence of depression and anxiety, which are believed to relate to the inhibition of the constitutive activity of the cannabinoid receptor.

Mutations in receptors that result in increased constitutive activity underlie some inherited diseases, such as precocious puberty+ (due to mutations in luteinizing hormone receptors) and hyperthyroidism+ (due to mutations in thyroid-stimulating hormone receptors).

The central-dogma of receptor-pharmacology is that a drug-effect is directly proportional to the number of receptors that are occupied. Furthermore, a drug effect ceases as a drug-receptor complex dissociates.

Ariëns+ and Stephenson introduced the terms "affinity" and "efficacy" to describe the action of ligands bound to receptors.

* Affinity+: The ability of a drug to combine with a receptor to create a drug-receptor complex.
* Efficacy+: The ability of a drug-receptor complex to initiate a response.

In contrast to the accepted ''occupation-theory'', rate-theory proposes that the activation of receptors is directly proportional to the total number of encounters of a drug with its receptors per unit-time. Pharmacological-activity is directly proportional to the rates of dissociation and association, '''not''' the number of receptors occupied:

* Agonist: A drug with a fast association and a fast dissociation.
* Partial-agonist: A drug with an intermediate-association and an intermediate-dissociation.
* Antagonist: A drug with a fast-association and slow-dissociation

As a drug approaches a receptor, the receptor alters the conformation of its binding-site to produce drug—receptor complex.

In some receptor-systems e.g. acetylcholine at the neuromuscular-junction in smooth-muscle, agonists are able to elicit maximal-response at very low-levels of receptor-occupancy (<1%). Thus that system has spare-receptors or a receptor-reserve. This arrangement produces an economy of neurotransmitter-production and release.

Cells can increase (upregulate+) or decrease (downregulate+) the number of receptors to a given hormone+ or neurotransmitter+ to alter their sensitivity to different molecule. This is a locally acting feedback+ mechanism.

* Change in the receptor conformation such that binding of the agonist does not activate the receptor. This is seen with ion channel receptors.
* Uncoupling+ of the receptor effector molecules+ is seen with G-protein couple receptor.
* Receptor sequestration+ (internalization). e.g. in the case of hormone receptors.

The ligands for receptors are as diverse as their receptors. Examples include:

| '''Receptor''' | '''Ligand''' | '''Ion current'''

| Nicotinic acetylcholine receptor+ | Acetylcholine+, Nicotine+ | Na+, K+, Ca2+

| Glycine receptor+ (GlyR) | Glycine+, Strychnine+ | Cl > HCO3

| GABA receptor+s: GABA-A, GABA-C | GABA+ | Cl > HCO3

| Glutamate receptor+s: NMDA receptor+, AMPA receptor+, and Kainate receptor+ | Glutamate+ | Na+, K+, Ca2+

| 5-HT3 receptor+ | Serotonin+ | Na+, K+

| P2X receptors+ | ATP+ | Ca2+, Na+, Mg2+

|

| '''Receptor''' | '''Ligand''' | '''Ion current'''

| cyclic nucleotide-gated ion channel+s | cGMP+ (vision+), cAMP+ and cGTP+ (olfaction+) | Na+, K+

| IP3 receptor+ | IP3+ | Ca2+

| Intracellular ATP+ receptors | ATP+ (closes channel) | K+

| Ryanodine receptor+ | Ca2+ | Ca2+
|

Many genetic disorder+s involve hereditary defects in receptor genes. Often, it is hard to determine whether the receptor is nonfunctional or the hormone+ is produced at decreased level; this gives rise to the "pseudo-hypo-" group of endocrine disorders+, where there appears to be a decreased hormonal level while in fact it is the receptor that is not responding sufficiently to the hormone.

The main receptors in the immune system+ are pattern recognition receptors+ (PRRs), toll-like receptor+s (TLRs), killer activated+ and killer inhibitor receptor+s (KARs and KIRs), complement receptor+s, Fc receptors+, B cell receptor+s and T cell receptor+s.

* Ki Database+
* Neuropsychopharmacology+
* Schild regression+ for ligand receptor inhibition
* Signal transduction+
* Stem cell marker+
* Wikipedia:MeSH D12.776#MeSH D12.776.543.750 – receptors.2C cell surface+

*
*
*

Cell_signaling:
Cell surface receptors:
Immune receptors:

genarch:

 Receptor (biochemistry)+ In biochemistry and pharmacology, a receptor is a protein molecule that receives chemical signals from outside a cell.